BioSpace

Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset

Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.

By BioSpace

1 min read
Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights